Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025
Anaptys (NASDAQ: ANAB) announced that complete Phase 2b data for rosnilimab in rheumatoid arthritis will be presented as a late-breaking oral at ACR Convergence 2025 in Chicago on Oct 29, 2025 from 8:00–9:30am CT.
The company described rosnilimab as a pathogenic T cell depleter that produced a compelling safety and tolerability profile and JAK-like efficacy through six months, with effects that were reported as durable for at least three months off-drug. Paul Emery, M.D., University of Leeds, will present (Abstract ID 2215555). The presentation will be available for download from the company website after the session.
Anaptys (NASDAQ: ANAB) ha annunciato che i dati completi di fase 2b per rosnilimab nel morbo reumatico verranno presentati come intervento orale late-breaking all'ACR Convergence 2025 a Chicago il 29 ottobre 2025 dalle 8:00 alle 9:30 (CT).
L'azienda ha descritto rosnilimab come un depletore di cellule T patogene che ha prodotto un profilo di sicurezza e tollerabilità convincente e un'efficacia simile a JAK per sei mesi, con effetti riportati come duraturi per almeno tre mesi senza farmaco. Il dottor Paul Emery, dell'Università di Leeds, presenterà (Abstract ID 2215555). La presentazione sarà disponibile per il download dal sito dell'azienda dopo la sessione.
Anaptys (NASDAQ: ANAB) anunció que los datos completos de la fase 2b de rosnilimab en la artritis reumatoide se presentarán como una charla oral de lógico tardío en ACR Convergence 2025 en Chicago el 29 de octubre de 2025 de 8:00 a 9:30 a.m. CT.
La empresa describió rosnilimab como un depeltor de células T patógenas que produjo un perfil de seguridad y tolerabilidad convincente y una eficacia al estilo JAK durante seis meses, con efectos reportados como duraderos durante al menos tres meses sin fármaco. El Dr. Paul Emery, de la Universidad de Leeds, presentará (Abstract ID 2215555). La presentación estará disponible para su descarga desde el sitio web de la empresa después de la sesión.
Anaptys (NASDAQ: ANAB) 는 류마티스 관절염에서 rosnilimab의 2b상 전체 데이터를 ACR Convergence 2025에서 시카고에서 열리는 마지막 발표 형식의 구두 발표로 2025년 10월 29일 8:00–9:30am CT에 발표할 것이라고 발표했습니다.
회사는 rosnilimab을 병원성 T세포 고갈제라고 설명했으며 매우 강력한 안전성 및 내약성 프로필과 6개월 간 JAK-유사 효능을 보였으며, 약물 중단 후 최소 3개월간 효과가 지속되는 것으로 보고되었습니다. 리즈 대학교의 Paul Emery 박사(M.D.)가 발표합니다(Abstract ID 2215555). 세션 이후 회사 웹사이트에서 발표자료를 다운로드할 수 있습니다.
Anaptys (NASDAQ: ANAB) a annoncé que les données complètes de la phase 2b pour rosnilimab dans la polyarthrite rhumatoïde seront présentées sous forme d'oral tardif lors de l'ACR Convergence 2025 à Chicago le 29 octobre 2025 de 8 h 00 à 9 h 30 CT.
L'entreprise a décrit rosnilimab comme un dépléteur de cellules T pathogènes qui a produit un profil de sécurité et de tolérance convaincant et une efficacité lik JAK pendant six mois, avec des effets rapportés comme durables pendant au moins trois mois sans traitement. Le Dr Paul Emery, de l'Université de Leeds, présentera (Abstract ID 2215555). La présentation sera disponible en téléchargement sur le site de l'entreprise après la session.
Anaptys (NASDAQ: ANAB) gab bekannt, dass vollständige Phase-2b-Daten zu rosnilimab bei rheumatoider Arthritis als später mündlicher Bericht auf der ACR Convergence 2025 in Chicago am 29. Oktober 2025 von 8:00 bis 9:30 Uhr CT präsentiert werden.
Das Unternehmen beschrieb rosnilimab als pathogenen T-Zell-Depletor, der ein überzeugendes Sicherheits- und Verträglichkeitsprofil und eine JAK-ähnliche Wirksamkeit über sechs Monate zeigte, mit Effekten, die als dauerhaft für mindestens drei Monate off-Drug gemeldet wurden. Dr. Paul Emery von der University of Leeds wird präsentieren (Abstract ID 2215555). Die Präsentation wird nach der Sitzung zum Download auf der Unternehmenswebseite verfügbar sein.
Anaptys (NASDAQ: ANAB) أعلنت أن البيانات الكاملة للمرحلة 2b لـ rosnilimab في التهاب المفاصل الروماتويدي ستعرض كعرض شفوي متأخر في ACR Convergence 2025 في شيكاغو يوم 29 أكتوبر 2025 من 8:00 إلى 9:30 صباحاً بتوقيت CT.
وصفَت الشركة rosnilimab بأنه مُزيل لخلايا T الممرِضة الذي أظهر ملف أمان وتحمل مقنع وفعالية على غرار JAK لمدة ستة أشهر، مع تأثيرات أُبلغ عنها بأنها دائمة لمدة لا تقل عن ثلاثة أشهر بعيداً عن الدواء. سيقدمها الدكتور بول إيموري من جامعة ليدز (Abstract ID 2215555). ستكون العرض قابلاً للتحميل من موقع الشركة بعد الجلسة.
Anaptys (NASDAQ: ANAB)宣布，rosnilimab在类风湿性关节炎中的完整2b期数据将作为晚期口头报告在ACR Convergence 2025于芝加哥举行，时间为2025年10月29日的8:00–9:30am CT。
公司描述 rosnilimab 为一种致病性T细胞清除剂，显示出一个<令人信服的安全性与耐受性轮廓和一个<六个月的JAK样疗效，其效应在停药至少三个月后仍被报告为持久。来自利兹大学的 Paul Emery 医学博士将进行报告（Abstract ID 2215555）。演讲结束后可从公司网站下载演示文稿。
- None.
- None.
SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that complete data from the Phase 2b trial of rosnilimab, a pathogenic T cell depleter, in rheumatoid arthritis (RA), was accepted for a late-breaking oral presentation at American College of Rheumatology (ACR) Convergence 2025 in Chicago, IL, Oct. 24 – 29, 2025.
“We are honored to be selected by ACR to present our late-breaking Phase 2b data for rosnilimab in RA,” said Paul Lizzul, chief medical officer of Anaptys. “Being selected reinforces the transformational potential of rosnilimab, which delivered a compelling safety and tolerability profile and JAK-like efficacy through six months that was durable for at least three months off-drug. We look forward to Professor Emery’s presentation later this month.”
Presentation Details:
- Abstract Title – Rosnilimab, a Selective and Potent Depleter of Pathogenic T Cells, Demonstrates Efficacy, Safety, and Translational Proof of Mechanism in a Rheumatoid Arthritis Phase 2b Trial
- Abstract ID - 2215555
- Session Date and Time - Wednesday, Oct. 29 from 8:00am – 9:30am CT
Paul Emery, M.D., professor, Rheumatology, University of Leeds, Leeds Biomedical Research Centre, U.K., will be the presenting author.
The presentation will be available for download on the Anaptys website after the session here.
About Rosnilimab
Rosnilimab is a novel therapeutic antibody that directly targets pathogenic T cells, such as activated Tph/Tfh and T effector cells, in the periphery or inflamed tissue. When activated, these T cells proliferate and migrate and secrete inflammatory cytokines that are the drivers of autoimmune and inflammatory diseases.
Rosnilimab is designed to selectively and potently deplete pathogenic T cells in both inflamed tissue and the periphery while sparing nonpathogenic T cells, including naïve T cells, to preserve overall immune function and restore immune homeostasis. This drives specific immunological outcomes, such as a reduction in T cell proliferation, migration and cytokine secretion, and a reduction of plasma cell generation and autoantibody levels.
About Anaptys
Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Its lead program, rosnilimab, a pathogenic T cell depleter, completed a Phase 2b trial for the treatment of rheumatoid arthritis and is in a Phase 2 trial for the treatment of ulcerative colitis. The company’s pipeline also includes ANB033, a CD122 antagonist, being studied in celiac disease and ANB101, a BDCA2 modulator, both in Phase 1 trials. Anaptys has also discovered and out-licensed in financial collaborations multiple therapeutic antibodies, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) to GSK and an IL-36R antagonist (imsidolimab) to Vanda Pharmaceuticals. To learn more, visit www.AnaptysBio.com or follow us on LinkedIn.
Anaptys recently announced the intent to separate its biopharma operations from its substantial royalty assets by year-end 2026, enabling investors to align their investment philosophies and portfolio allocation with the strategic opportunities and financial objectives of each company. Learn more here.
Contact:
Nick Montemarano
Executive Director, Investor Relations
858.732.0178
investors@anaptysbio.com
FAQ
When will Anaptys (ANAB) present rosnilimab Phase 2b data at ACR Convergence 2025?
What clinical results will Anaptys (ANAB) report for rosnilimab in RA from the Phase 2b trial?
Who will present Anaptys (ANAB) Phase 2b rosnilimab data at ACR Convergence 2025?
Where can investors access the Anaptys (ANAB) rosnilimab presentation after ACR Convergence 2025?
What is the abstract ID for the Anaptys (ANAB) rosnilimab Phase 2b presentation?
